AstraZeneca

A Biotech Roller Coaster
Motley Fool
Sat, 01/8/11 - 11:57 am
Lexicon Pharmaceuticals
diabetes
LX4211
Merck
obesity
Amylin
Januvia
Onglyza
Bristol-Myers Squibb
AstraZeneca
AstraZeneca: FDA Extends Vandetanib NDA Review Timeline To April 7
WSJ Online
Fri, 01/7/11 - 10:07 am
FDA
NDA
vandetanib
AstraZeneca
This NICE Deal Could Foreshadow 2011
Motley Fool
Fri, 12/31/10 - 10:55 am
NICE
GSK
Pfizer
Human Genome Sciences
Bristol-Myers Squibb
Merck
AstraZeneca
value-based pricing
The Painful Death of a Promising Drug Class
Motley Fool
Thu, 12/30/10 - 10:53 am
Regeneron
Sanofi
JNJ
AstraZeneca
NGF-1
The Most Promising Dividends in Pharmaceuticals
Motley Fool
Wed, 12/29/10 - 11:48 am
dividends
Eli Lilly
GSK
Bristol-Myers Squibb
Pfizer
Merck
Abbott Laboratories
JNJ
Merdian
Sanofi
Novartis
AstraZeneca
Teva Pharmaceuticals
Novo Nordisk
Abbott the Only One Left in the Osteoarthritis Game
Seeking Alpha
Wed, 12/29/10 - 11:28 am
Abbott Laboratories
osteoarthritis
JNJ
AstraZeneca
Pfizer
Regeneron
Sanofi
AstraZeneca's Brennan Poaches Pfizer to Rebuild Research
Bloomberg
Wed, 12/29/10 - 10:47 am
Pfizer
R&D
AstraZeneca
David Brennan
Pharma CEOs
J&J, AstraZeneca Halt Experimental Pain Drug Tests on Bone-Damage Concern
Bloomberg
Tue, 12/28/10 - 10:56 am
JNJ
AstraZeneca
Deals to Be Done After AstraZeneca Setback
WSJ Online
Thu, 12/23/10 - 08:26 am
AstraZeneca
RSV
Cubist Pharmaceuticals
NanoBio
MicroDose Therapeutx
Novavax
Synagis
motavizumab
Alnylam
AstraZeneca, Abbott end Certriad license deal
Marketwatch
Wed, 12/22/10 - 09:52 pm
Certriad
AstraZeneca
Abbott Laboratories
dyslipidemia
AstraZeneca Halts Drug, Takes Big Charge
TheStreet.com
Tue, 12/21/10 - 10:07 am
AstraZeneca
motavizumab
RSV
Brilinta rejection adds to AstraZeneca's patent expiration woes
Fierce Biotech
Mon, 12/20/10 - 01:13 pm
patents
FDA
Brilinta
AstraZeneca
AstraZeneca's Blood-Thinner Hits Another FDA Roadblock as Company Faces Patent Cliff
Seeking Alpha
Sun, 12/19/10 - 12:15 pm
AstraZeneca
Brilinta
blood thinners
Astrazeneca Tumbles On FDA Delay For Blood Thinner
Forbes
Sat, 12/18/10 - 12:38 pm
AstraZeneca
blood thinners
Brilinta
Director Of Equity Research At RBC Capital Markets Covers Phase III Data For Multiple New Drugs; Find Out The Stocks That Investors Should Look At
Yahoo/Wall Street Transcript
Sat, 12/18/10 - 12:24 pm
Athenahealth
Abbott Laboratories
Beckman Coulter
Agilent
AstraZeneca
Provenge
Dendreon
Benlysta
Human Genome Sciences
Telaprevir
Vertex Pharmaceuticals
AstraZeneca Fails to Win U.S. FDA Approval for Plavix Competitor Brilinta
Bloomberg
Thu, 12/16/10 - 11:02 pm
FDA
AstraZeneca
Brilinta
blood thinners
Plavix
FDA’s Brilinta Vote Seen Key for AstraZeneca Share Price
WSJ Online
Tue, 12/14/10 - 11:25 am
FDA
Brilinta
AstraZeneca
blood thinners
Pfizer's Asia Head of R&D Leaves for AstraZeneca
Seeking Alpha
Mon, 12/13/10 - 08:31 pm
Pfizer
Asia
R&D
AstraZeneca
Biotech Calendar: FDA Drug Approvals in 2011
TheStreet.com
Mon, 12/13/10 - 12:26 pm
MannKind
Afrezza
Alimera
pSivida
Seattle Genetics
brentuximab vedotin
Illuvien
AstraZeneca
Zictifa
Clinical Data
Vilazodone
Orexigen
Contrave
Bristol-Myers Squibb
Yervoy
Pfizer
Protalix BioTherapeutics
UPLYSO
Xiafaxan
Salix
Human Genome Sciences
Benlysta
Dendreon
Provenge
InterMune
Esbriet
Cell Therapeutics
pixantrone
Forest Labs
Daxas
MELA Sciences
MelaFind
XenoPort
GSK
Horizant
Spectrum Pharmaceuticals
Fusilev
Adventrx
Vertex Pharmaceuticals
Telaprevir
Pfizer, Novartis, AstraZeneca Cancer Drugs Increase Heart Risks
Bloomberg
Thu, 12/9/10 - 12:08 pm
Pfizer
Novartis
AstraZeneca
Aromasin
Femara
Arimidex

Pages